Welcome to our dedicated page for Wave Life Scienc news (Ticker: WVE), a resource for investors and traders seeking the latest updates and insights on Wave Life Scienc stock.
Wave Life Sciences Ltd. develops RNA medicines as a clinical-stage biotechnology company, using its PRISM platform to design oligonucleotides across RNA editing, RNA interference and antisense silencing. Company news commonly centers on clinical and regulatory updates for investigational programs such as WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, and WVE-007, an INHBE GalNAc-siRNA evaluated for obesity and cardiometabolic disease biology.
Updates also cover financial results, corporate presentations, platform expansion, collaboration activity involving PRISM, and governance or capital-structure matters. Recurring scientific disclosures include trial data presentations, safety and tolerability findings, regulatory engagement, and pipeline work in liver, muscle and neurologic diseases.
Wave Life Sciences announced key developments in its third quarter 2022 report, highlighting progress in clinical trials for Huntington’s disease (WVE-003) and Duchenne muscular dystrophy (WVE-N531). The SELECT-HD trial showed safe, well-tolerated doses and a reduction in mutant huntingtin protein. WVE-006 was selected for alpha-1 antitrypsin deficiency, with CTA submissions expected in 2023. Financially, the company reported a net loss of $39 million and a significant revenue drop to $0.3 million, mainly due to prior collaboration amendments. Cash on hand is $122 million, expected to last through 2023.
Wave Life Sciences Ltd. (Nasdaq: WVE) announced that CEO Paul Bolno will participate in an analyst-led fireside chat at the Stifel 2022 Healthcare Conference in New York City on November 16, 2022, at 3:35 p.m. ET. This event focuses on the company's commitment to developing genetic medicines for devastating diseases. A live webcast of the discussion will be available on the company’s Investor Relations page, with replays accessible for a limited time post-event.
Wave Life Sciences (Nasdaq: WVE) announced a conference call scheduled for 8:30 a.m. ET on November 10, 2022, to discuss its Q3 2022 financial results and provide a business update. The call will be accessible via the company’s investor relations webpage. Wave Life Sciences is a clinical-stage genetic medicines company focused on developing treatments for severe diseases using its proprietary PRISM platform for drug development. The archived call will also be available post-event.
Wave Life Sciences Ltd. (Nasdaq: WVE) announced its participation in upcoming scientific conferences to showcase advancements in oligonucleotide chemistry and RNA editing. This includes preclinical data for WVE-006, targeting alpha-1 antitrypsin deficiency, which is presented for the first time. The presentations at the Oligonucleotide Therapeutics Society and European Society of Gene & Cell Therapy meetings will emphasize the company's proprietary discoveries and drug development capabilities.
Wave Life Sciences highlighted its advanced candidate, WVE-006, for treating alpha-1 antitrypsin deficiency (AATD) during a recent virtual event. The RNA editing program aims to correct genetic mutations and restore functional protein levels. Preclinical data show a significant increase in AAT protein production and functional activity. Clinical trial applications for WVE-006 are expected to be submitted in 2023. Wave is also exploring broader applications for its AIMers technology beyond AATD, potentially impacting multiple diseases.
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company, announced that CEO Paul Bolno will participate in an analyst-led fireside chat at Chardan’s 6th Annual Genetic Medicines Conference on October 4, 2022, at 3:15 p.m. ET in New York City. A live webcast of the event will be accessible on the company's Investor Relations page, with a replay available for a limited time afterward. Wave Life Sciences focuses on developing innovative treatments for genetically defined diseases through its proprietary PRISM platform.
Wave Life Sciences Ltd. announces positive results from the SELECT-HD Phase 1b/2a clinical trial of WVE-003, a candidate for treating Huntington’s disease. Single doses of 30 or 60 mg led to a mean reduction of 22% in mutant huntingtin protein levels in cerebrospinal fluid, with a median reduction of 30%. The treatment was reportedly well-tolerated, with no serious adverse events. Wave plans to expand the dosing cohorts and has early data supporting allele-selective knockdown of the harmful protein. Further updates are expected in 1H 2023.
Wave Life Sciences (Nasdaq: WVE) announced an analyst and investor webcast on September 28, 2022, focusing on WVE-006, its first-in-class RNA editing candidate targeting alpha-1 antitrypsin deficiency (AATD). The event, titled 'Towards the Clinic: Spotlight on RNA Editing for AATD', will provide insights from AATD expert Dr. D. Kyle Hogarth and the Wave management team. WVE-006 aims to correct mutations in the SERPINA1 gene, addressing both lung and liver disease. Registration is available on Wave's website.
Wave Life Sciences (WVE) announced the selection of WVE-006 as its first RNA editing candidate for treating alpha-1 antitrypsin deficiency (AATD), with clinical trial applications expected in 2023. The company reported a net loss of $41.3 million for Q2 2022, down from $38.8 million a year earlier, with revenue declining to $0.4 million. Research and development expenses were $29.7 million, while general and administrative expenses increased to $12.8 million. A successful financing round in June 2022 raised $70 million, strengthening the balance sheet and providing cash runway until the end of 2023.
Wave Life Sciences (Nasdaq: WVE) will host a live webcast and conference call on August 11, 2022, at 8:30 a.m. ET to review its Q2 2022 financial results and provide a business update. Investors can access the webcast through the company's investor relations website. Analysts are encouraged to register in advance for the Q&A session. Wave Life Sciences focuses on developing genetic medicines for severe diseases, using its proprietary PRISM platform to create stereopure oligonucleotides.